November 16th, 2026Diabetes Dialogue: OPTIMAL-DIABETES, Survodutide, and Orforglipron at AHA 2026Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.Read more
November 12th, 2026Diabetes Dialogue: Retatrutide Tops Semaglutide on A1C, Weight in T2DTRANSCEND-T2D-2 topline data show retatrutide lowered A1C more and produced over twice the weight loss of semaglutide 2 mg in type 2 diabetes.Read more
November 12th, 2026Diabetes Dialogue: CONNECT Trial Backs CGM in Non-Insulin Type 2 DiabetesTom Martens, MD, joins Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss CONNECT trial data on CGM in non-insulin-treated type 2 diabetes.Read more
November 16th, 2026Diabetes Dialogue: Tubeless Mobi Clearance, CGM Choice, and Eversense FreedomDiana Isaacs, PharmD, and Natalie Bellini, DNP, discuss tubeless Mobi's FDA clearance, CVS Caremark's CGM formulary shift, and a transmitter-free implant.Read more
November 9th, 2026The HCPFive: Top News for Healthcare Providers from the Week of 11/1Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.Read more
November 8th, 2026SHASTA-3/4: Plozasiran Could Cut Acute Pancreatitis Risk by 78% Across sHTG SpectrumIn 757 adults with severe hypertriglyceridemia, plozasiran cut acute pancreatitis events by 78% overall and 91% in those with recent prior pancreatitis.Read more
November 16th, 2026FDA Updates Aficamten Label With MAPLE-HCM Data in Obstructive HCMAficamten's label now includes MAPLE-HCM data, in which aficamten monotherapy improved peak VO2 by 2.3 mL/kg/min more than metoprolol at 24 weeks.Read more
November 16th, 2026FDA Approves Dexmedetomidine for At-Home Schizophrenia, Bipolar AgitationDexmedetomidine sublingual film is the first FDA-approved at-home option for acute agitation, based on the phase 3 SERENITY at-home trial.Read more